Recombinant Human Epidermal Growth Factor/EGF

Cat.No.: C029

Recombinant Human EGF
Description
Recombinant Human Epidermal Growth Factor is produced by our E.coli expression system and the target gene encoding Asn971-Arg1023 is expressed.
Accession #:P01133
Known as:Pro-Epidermal Growth Factor; EGF; Epidermal Growth Factor; Urogastrone
Formulation
Lyophilized from a 0.2 μm filtered solution of 20mM Tris, 200mM NaCl, pH 8.0.
Quality Control
Purity:Greater than 95% as determined by reducing SDS-PAGE.
BioActivity:Measured in a cell proliferation assay using BALB/c 3T3 cells.The ED50 for this effect is 60-450 pg/ml.
Endotoxin:Less than 0.1 ng/?g (1
Reconstitution
Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100 μg/ml.
Dissolve the lyophilized protein in ddH2O.
Please aliquot the reconstituted solution to
Storage
Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Background
Epidermal growth factor (EGF) is a small 53 amino acid residue long protein that contains three disulfide bridges. It is a small mitogenic protein that is thought to be involved in mechanisms such as normal cell growth, oncogenesis, and wound healing. EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. This protein shows both strong sequential and functional homology with human type-alpha transforming growth factor (hTGF alpha), which is a competitor for EGF receptor sites.
Publication
Use of Peptides That Block Metadherin-SND1 Interaction as Treatment for Cancer Kang Yibin, et al. (The Trustees of Princeton University patent:US20190336574 2019)+
The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells.
Use of peptides that block metadherin-SND1 interaction as treatment for cancer Kang Yibin, et al. (THE TRUSTEES OF PRINCETON UNIVERSITY patent:10357539 2019)+
The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells.
Human anti-human epidermal growth factor receptor antibody and encoding gene and application thereof Sun Zhiwei, et al. (Shanghai serum biotechnology Co., LTD. patent:9840561 2017)+
The present invention provides human anti-human epidermal growth factor receptor (EGFR) antibodies and their encoding genes and applications thereof. By gene engineering means and phage surface display technology, the present invention screens anti-human EGFR gene engineering single chain antibody from fully synthetic single chain human antibody library, and obtains the antibody variable gene sequence thereof, and based thereon, constructs intact human monoclonal antibody, to further obtain high-purity antibody protein. The binding affinity of the antibody of the present invention with human EGFR is no more than 1 nM, and the mutants affinity thereof is no more than 10 nM; and the identification of the immunity activity and bioactivity of antibodies protein IgG is completed, confirming that the antibody of the present invention has good bioactivity of inhibiting the tumor growth of EGFR expressing cell A431 tumor-bearing model mouse. The antibodies of the present invention provides specific antibody drugs for preventing and treating EGFR targeted tumor and other diseases such as inflammation and autoimmune diseases.
USE OF PEPTIDES THAT BLOCK METADHERIN- SND1 INTERACTION AS TREATMENT FOR CANCER Kang Yibin, et al. (THE TRUSTEES OF PRINCETON UNIVERSITY patent:US20170189481 2017)+
The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells.
β-Spectrin regulates the Hippo signaling pathway and modulates the basal actin network Wong K K L, et al. (Journal of Biological Chemistry, 2015)+

Send Message